TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04444700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation
Description: The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
Study: NCT02160977

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total knee arthroplasty
Study: NCT02595879

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose Rate Brachytherapy
Description: Undergo HDR brachytherapy
Study: NCT04061473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: 2 tablets of empagliflozin 25 mg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 2 placebo tablets.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol.
Study: NCT02595879

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT03922750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine U100
Description: Participants will receive s.c. injections of insulin glargine OD for 16 weeks
Study: NCT01627431

Intervention type: DRUG
Group type: OTHER
Intervention: Acetylsalicylic acid
Description: 100 mg once per day

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel
Description: 75 mg once per day
Study: NCT02595879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triapine
Description: Given IV and PO
Study: NCT01918813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin, mupirocin ointment
Description: contact precautions, topical decolonization of MRSA by a bath with 4% chlorhexidine daily for 3-5 days
Study: NCT02604667

Intervention type: OTHER
Intervention: Blood tests
Description: Study participants will undergo a single, peripheral blood draw. Blood specimens will be used to perform hematological biomarker testing and leukocyte RNA gene expression analysis.~Hematological biomarker testing will be performed to better elucidate the mechanisms of ischemic stroke in cancer patients and will include markers of coagulation, platelet function, and endothelial integrity. This analysis will occur at MSKCC.~Leukocyte RNA gene expression analysis will be performed to evaluate whether patients with cancer and stroke more often have cardioembolic mechanisms than patients with stroke and no cancer. This analysis will occur at the University of California, Davis where investigators have previously shown that differential RNA expression patterns can predict stroke subtypes.

Intervention type: OTHER
Intervention: Blood tests
Description: Study participants will undergo a single, peripheral blood draw. Blood specimens will be used to perform hematological biomarker testing and leukocyte RNA gene expression analysis.~Hematological biomarker testing will be performed to better elucidate the mechanisms of ischemic stroke in cancer patients and will include markers of coagulation, platelet function, and endothelial integrity. This analysis will occur at MSKCC.~Leukocyte RNA gene expression analysis will be performed to evaluate whether patients with cancer and stroke more often have cardioembolic mechanisms than patients with stroke and no cancer. This analysis will occur at the University of California, Davis where investigators have previously shown that differential RNA expression patterns can predict stroke subtypes.
Study: NCT04289987

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVI-HBV-002
Description: Investigational Product

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline(placebo)
Description: Investigational Product
Study: NCT02604667

Intervention type: OTHER
Intervention: Blood tests
Description: Study participants will undergo a single, peripheral blood draw. Blood specimens will be used to perform hematological biomarker testing and leukocyte RNA gene expression analysis.~Hematological biomarker testing will be performed to better elucidate the mechanisms of ischemic stroke in cancer patients and will include markers of coagulation, platelet function, and endothelial integrity. This analysis will occur at MSKCC.~Leukocyte RNA gene expression analysis will be performed to evaluate whether patients with cancer and stroke more often have cardioembolic mechanisms than patients with stroke and no cancer. This analysis will occur at the University of California, Davis where investigators have previously shown that differential RNA expression patterns can predict stroke subtypes.

Intervention type: OTHER
Intervention: Transcranial Doppler Microemboli Detection Study
Description: Study participants will undergo a single Transcranial Doppler Microemboli Detection Study at NYPH/WCMC or MSKCC within two weeks of enrollment. Both middle cerebral arteries will be insonated for 30 minutes by a trained technician or stroke neurologist certified in neurosonology using a fixed headset to assess for the rate and laterality of microemboli.
Study: NCT04367194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation
Description: After examination of the patients, the patients undergo neurorehabilitation. We use virtual reality therapy. Patients perform a submaximal load that is monitored by a polar clock. We develop endurance, coordination, sensory integration, visual and acoustic input, vestibular training, proprioception training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation
Description: After examination of the patients, the patients undergo neurorehabilitation. We use virtual reality therapy. Patients perform a submaximal load that is monitored by a polar clock. We develop endurance, coordination, sensory integration, visual and acoustic input, vestibular training, proprioception training.
Study: NCT02604667

Intervention type: OTHER
Intervention: Transcranial Doppler Microemboli Detection Study
Description: Study participants will undergo a single Transcranial Doppler Microemboli Detection Study at NYPH/WCMC or MSKCC within two weeks of enrollment. Both middle cerebral arteries will be insonated for 30 minutes by a trained technician or stroke neurologist certified in neurosonology using a fixed headset to assess for the rate and laterality of microemboli.
Study: NCT04367194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation
Description: After examination of the patients, the patients undergo neurorehabilitation. We use virtual reality therapy. Patients perform a submaximal load that is monitored by a polar clock. We develop endurance, coordination, sensory integration, visual and acoustic input, vestibular training, proprioception training.
Study: NCT01513967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPh201, botanical drug product
Description: SC administration at varying doses
Study: NCT01079390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: patient will receive high dose, low dose or sham acupuncture treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: patient will receive high dose, low dose or sham acupuncture treatment.
Study: NCT01513967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPh201, botanical drug product
Description: SC administration at varying doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPh201, botanical drug product
Description: SC administration at varying doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPh201, botanical drug product
Description: SC administration at varying doses
Study: NCT01079390

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: acupuncture
Description: patient will receive high dose, low dose or sham acupuncture treatment.
Study: NCT00159874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: Oral, subjects with body weight ≥8 - 20 kg: 20 mg 3 times a day (tid) subjects with body weight \>20 - 45 kg: 40 mg 3 times a day (tid) subjects with body weight \>45 kg: 80 mg 3 times a day (tid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: Oral,10 mg 3 times a day (tid), only subjects with body weight \>20 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: Oral, subjects with body weight ≥8 - 20 kg: 10 mg 3 times a day (tid); subjects with body weight \>20 - 45 kg: 20 mg 3 times a day (tid); subjects with body weight \>45 kg: 40 mg 3 times a day (tid)
Study: NCT01436890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revamilast
Description: Tablet. Low dose, Once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revamilast
Description: Medium dose, Once daily for 12 weeks
Study: NCT01513967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPh201, botanical drug product
Description: SC administration at varying doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC administration at varying doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC administration at varying doses
Study: NCT01436890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revamilast
Description: High dose, Once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet in triple dummy format, Once daily for 12 weeks
Study: NCT01313325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: Children will receive treatment by a licensed physical therapist using hippotherapy as the treatment strategy. This includes sitting on a horse who's movement is controlled by a horse leader, with the PT directing the movements required of the horse, as well as supplying supplemental cues to the participant. Alternative positions (such as sitting backward and sideways) may also be used during the treatment session.
Study: NCT01515254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle counseling, parental feeding
Description: Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
Study: NCT01122680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide
Description: inhalation solution, dose of 1.25 mcg (2 puffs of 0.625 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide
Description: inhalation solution, dose of 2.5 mcg (2 puffs of 1.25 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide
Description: inhalation solution, dose of 5 mcg (2 puffs of 2.5 mcg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo inhalation solution
Study: NCT01513967

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC administration at varying doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC administration at varying doses
Study: NCT00692237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 100 mg daily (3 capsules/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 100 mg (3 capsules/day)
Study: NCT03683498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regulatory T-cell enriched infusion
Description: Enrichment of CD25hi regulatory T cells from CD8 and/or CD19 pre-depleted leukapheresis products.
Study: NCT02570425

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Training on BF Spiromax followed by SYMBICORT Turbohaler
Description: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Training on BF Spiromax followed by SYMBICORT Turbohaler
Description: Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Training on SYMBICORT Turbohaler followed by BF Spiromax
Description: Training with a placebo comparator: SYMBICORT Turbohaler® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Training on SYMBICORT Turbohaler followed by BF Spiromax
Description: Training with a placebo comparator: SYMBICORT Turbohaler® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
Study: NCT01579877

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herbal extract granule
Description: The herbal extract granule, Yukmijihwang-tang granule, consists of 6 herbs. Ingredients: Rehmanniae Radix, Deoscoreae Radix, Corni Fructus, Hoelen, Alismatis Radix, Paeoniae Radicis Cortex. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo herbal extract granule
Description: The Yukmijihwang-tang_Placebo has the same form, color and flavor as experimental intervention (Yukmijihwang-tang). The dosage, frequency and duration is also the same as experimental intervention (Yukmijihwang-tang).
Study: NCT00964522

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nurse education and care program
Description: Random allocation of the patients in two arms according to the nursing cares. The arm A is the one of standard education and care. They consist of receiving programmed oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle of treatment. Also, the patients will be able to ask for information to the nurses when they need it. Arm B is the one of experimental education and care. They consist of receiving oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle. In addition, the patients assigned to arm B will receive programmed education and care about the chemotherapy by a Oncology nurse before the beginning of the treatment and in each cycle, in a specific nurse consultation.
Study: NCT02219451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: exercise training
Study: NCT03692026

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant placement
Description: implants will be placed in freshly extraction sockets with or without application of Hyaluronic acid and Melatonin mixture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant placement
Description: implants will be placed in freshly extraction sockets with or without application of Hyaluronic acid and Melatonin mixture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid and Melatonin Mixture
Description: a mixture of hyaluronic acid and melatonin will be prepared and added topically to the implant surface, extraction socket and peri-implant area for the study group
Study: NCT02035228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Stimulation - low / early
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current for the first half of exhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal stimulation - low/late
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current for the second half of exhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Stimulation - low/full
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current throughout exhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal stimulation - med/early
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current for the first half of exhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal stimulation - med/late
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current for the second half of exhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Stimulation - med/full
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current throughout exhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Stimulation - high/early
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at high stimulation current for the first half of exhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Stimulation - high/late
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at hig stimulation current for the second half of exhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Stimulation - high/full
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at high stimulation current throughout exhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Stimulation - high/full
Description: Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at high stimulation current throughout exhalation
Study: NCT00276380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGb761
Description: EGb761 (Tanakan) 40 mg tablets (2 tablets t.i.d. (3 times a day)) 240 mg/day for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 40 mg tablets (2 tablets t.i.d.) 240 mg/day for 6 months.
Study: NCT01046084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: 30 mg Delayed-Release Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevacid®
Description: 30 mg Delayed-Release Capsule
Study: NCT03681977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer MP Persona
Description: The medial pivot Persona® knee implant with a Medial Congruent™ Bearing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer Persona Knee-PS
Description: Persona the personalized knee system
Study: NCT03155867

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal replacement
Description: The study interventions contain protein, carbohydrate and fat and are intended for use as complete meal replacements for weight loss.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal replacement
Description: The study interventions contain protein, carbohydrate and fat and are intended for use as complete meal replacements for weight loss.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal replacement
Description: The study interventions contain protein, carbohydrate and fat and are intended for use as complete meal replacements for weight loss.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal replacement
Description: The study interventions contain protein, carbohydrate and fat and are intended for use as complete meal replacements for weight loss.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal replacement
Description: The study interventions contain protein, carbohydrate and fat and are intended for use as complete meal replacements for weight loss.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal replacement
Description: The study interventions contain protein, carbohydrate and fat and are intended for use as complete meal replacements for weight loss.
Study: NCT03261843

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous platelet rich plasma
Description: adding autologous platelet rich plasma to the bone graft harvested from the patient

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterior lumbar interbody fusion without autologous platelet rich plasma
Description: performing posterior lumbar interbody fusion without using platelet rich plasma
Study: NCT04456738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: 16 weeks of of parent training led by a trained group facilitator
Study: NCT00276380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.
Study: NCT03903341

Intervention type: OTHER
Group type: OTHER
Intervention: fMRI
Description: bold signal in visual pathway